

CARA Systems is a New York-based health tech company, **building SaaS solutions for neurovascular conditions with high clinical uncertainty**. We help clinicians identify high-risk patients earlier, prioritize care more effectively, and guide personalized triage and care management through non-invasive, patient-specific risk assessment.

350+

stakeholder interviews

2,000+

patient validation completed
NYULH & Bellevue Hospital

93%

rupture-risk models accuracy

EPIC

approved vendor since Aug 2026

THE PROBLEM

- **7 million Americans** live with an unruptured brain aneurysm (Brain Aneurysm Foundation). About 30,000 ruptures annually, with 50% mortality and 66% morbidity in survivors.
- **8 to 12 weeks** of fragmented review, repeat imaging, specialist consultations, and sometimes invasive testing
- **No reliable, non-invasive patient-specific assessment** consolidates the relevant risk signals
- **\$200,000+ per patient** in potential downstream costs when diagnosis, rupture, or treatment is delayed.

The question we help clinicians answer: What does this patient's aneurysm risk mean clinically, and does it support intervention, closer surveillance, or routine monitoring?

OUR SOLUTION

AneuView™, is a cloud-based clinical diagnostic and decision-support platform that converts fragmented patient information into one interpretable risk assessment framework.

- **Multimodal intelligence:** non-invasive CTA/MRA imaging analysis, patient-specific hemodynamics, clinical biomarkers, and longitudinal change
- **Clinician-directed:** supports, rather than replaces, clinical judgment
- **Workflow native:** integrates with EHR and PACS environments and requires no new hardware

STUDY-INDICATED AND PROJECTED VALUE

CLINICIANS	HOSPITALS	PAYERS
< 1 hour	20-30%	\$60-80K
to an integrated risk assessment	better diagnostic reliability; 50-70% less workload	potential savings per patient from fewer scans and tests

TARGET MARKET AND CUSTOMER

- **Beachhead:** U.S. academic medical centers and comprehensive stroke centers
- **Institutional buyers:** hospital innovation, digital health, and neurovascular service-line leaders
- **Clinical users:** neuroradiologists, vascular neurologists, neurosurgeons, and neuro interventionalists
- **Market:** \$50 billion global TAM and \$1 billion immediately addressable U.S.

BUSINESS MODEL

Our staged and flexible enterprise model supports adoption before reimbursement.

- **One-time implementation fee** for security, integration, workflow configuration, and onboarding
- **Recurring enterprise platform fee** for broad clinician access, hosting, and support
- **Patient-specific assessment fee** for each newly completed clinical analysis
- **\$1.35M ARR** target through high-volume institutional deployments

Paid pilots validate clinical value, enterprise contracts drive adoption after clearance, and reimbursement-aligned fees support scale.

TRACTION AND VALIDATION

- **350+ stakeholder interviews** across U.S. institutions shaped product design, workflow, and adoption strategy
- **2,000+ patient records** included in validation studies with NYU Langone Health and Bellevue Hospital
- **93% accuracy** for the early rupture-risk models
- **NYU Langone Health pilot process underway**, and developing pilot pathways with additional institutions
- **EPIC-approved vendor** since August 2026, supporting embedded hospital deployment
- **Regulatory pathway defined:** FDA Q-Submission and coordinated Class II 510(k) pathway, advancing alongside pilots
- **Patent-pending technology** with exclusive commercial rights

"CARA's platform has fundamentally transformed how we approach risk evaluation and triage. Its AI-driven analytics enable us to synthesize critical insights in real time."

Albert S. Favate, MD,

Division Chief, Vascular Neurology, NYU Langone Health

STRATEGIC SUPPORT WE ARE SEEKING

THE ASK: \$1.325M TO CLOSE \$2M PRE-SEED

- **Raised to date:** \$875K from grants, accelerators, and friends and family, including \$675K secured toward this round.
- **18-month milestones:** enterprise-ready platform; advance FDA Q-Submission and 510(k); run institutional pilots; convert at least five institutions to paying customers with contracts.
- **Beyond capital:** introductions to health-system operators and neurovascular leaders (pilots), healthcare AI and medical-device investors, and regulatory, reimbursement, payer, and distribution partners.

TEAM

Core Team

[Prithvinath Reddy G.](#), Co-Founder & CEO
MS, Medical Robotics, NYU

[Srushiti Katore](#), Co-Founder & COO
MS, Medical Robotics, NYU

[Kurt H. Becker PhD](#), Advisor & Director of Business Development
Former Vice Dean Research Innovation and Entrepreneurship NYU

[Hemanth Krishna T.](#), Founding Engineer
Researcher, NYU

Clinical And Industry Advisors

[Albert S. Favate, MD](#)
Division Chief, Vascular Neurology, NYU Langone

[Seth Tropper](#) and [Yair Harel](#)
Managing Partners, XPI Venture Partners

[Doug Nissinoff](#)
Founder and General Partner, Intelligence Ventures